Argatroban could revive the practice of acute anticoagulation for reducing disability after stroke, based on the EASE trial from China. In patients with acute ischemic stroke and early neurological ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

(San Diego, Calif., December 7, 2003) – The use of ximelagatran in patients with acute venous thromboembolism is as safe and effective as the current standard treatment of enoxaparin, according to a ...

Direct thrombin inhibitors prevent the conversion of fibrinogen into fibrin during the coagulation cascade and ultimately prevent the development of a thrombus. 11 Dabigatran etexilate was the first ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

Potent new anticoagulants have been discovered in the genetic code responsible for the saliva of blood-sucking ticks. Anticoagulants, also known as blood thinners, help prevent unwanted blood clotting ...

Coadministration of dabigatran etexilate with the antiplatelet drug clopidogrel had no effect on dabigratran's anticoagulant activity as measured by ECT, activated partial thromboplastin time (aPTT), ...

Among patients with atrial fibrillation (AF), use of factor Xa inhibitors for stroke prevention is associated with a greater risk of interstitial lung disease (ILD) than use of warfarin, although the ...

Thrombosis, the clogging of blood vessels, is a major cause of heart attacks and embolism. Scientists have now engineered the first inhibitors of thrombin, a protease promoting thrombosis, that is ...